Protalix Biotherapeutics, Inc.

From Protalix Biotherapeutics's results release of 10 Kasım 2026; its quarterly report has since been filed.

• Revenue

  Actual

  $21,9M

  +%23 y/y ↑
  +%10 q/q ↑

  Guided

  —

  No guide given

• EPS, GAAP

  Actual

  $0,05

  +%67 y/y ↑
  %0,0 q/q →

  Guided

  —

  No guide given

• Operating income, GAAP

  Actual

  $4M

  +%90 y/y ↑
  -%13 q/q ↓

  Guided

  —

  No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.